Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Exp Eye Res ; 168: 49-56, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29326066

RESUMEN

In the present study, therapeutic effect of topically applied everolimus (EV)-loaded methoxy-poly(ethylene-glycol)-hexyl substituted poly (lactic acid) (mPEGhexPLA) nanocarriers on experimental autoimmune uveoretinitis (EAU) were investigated. EAU was induced in B10.RIII mice via immunization with human interphotoreceptor retinoid-binding protein peptide 161-180 (hIRBPp161-180) in complete Freund's adjuvant. Everolimus-loaded mPEGhexPLA (EV/mPEGhexPLA) nanocarriers were prepared by using a solvent evaporation method. On days 12-21 postimmunization (p.i.), the right eyes were treated five times daily either with 10 µl of 0.5% everolimus formulation or PBS (control). The EAU score of the eyes was determined histologically. On day 21 p.i., the peripheral immune responses were measured in serum, cervical lymph nodes (LN), and spleens via hIRBPp161-180-specific serum antibodies, cytokine secretion (ELISA), lymphocyte proliferation, and FoxP3+ regulatory T cells (Treg; flow cytometry). Compared to the PBS-treated mice, unilateral topical everolimus treatment significantly reduced EAU severity in both eyes (p < .05). The treatment reduced the antigen (Ag)-specific hIRBPp161-180-induced proliferation (p < .05), IL-2, IL-17, and IFN-γ secretion from cells isolated from the left and right cervical LN (p < .05). Under everolimus treatment, IL-10 secretion and CD4+CD25+FoxP3+ Treg frequency from cervical LN were enhanced. The proliferative response and cytokine secretion as well as the frequency of splenic Treg were almost unchanged. Topical administration of an everolimus formulation improved EAU in both eyes. The effect might also be related to systemic immunosuppressive effects, as several systemic cellular immune responses were influenced.


Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Sistemas de Liberación de Medicamentos/métodos , Everolimus/administración & dosificación , Inmunosupresores/administración & dosificación , Nanocápsulas/uso terapéutico , Retinitis/tratamiento farmacológico , Animales , Autoanticuerpos/sangre , Proliferación Celular/efectos de los fármacos , Citocinas/metabolismo , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Interferón gamma/metabolismo , Activación de Linfocitos/efectos de los fármacos , Ratones , Retinitis/inmunología , Bazo/metabolismo
2.
J Control Release ; 275: 32-39, 2018 04 10.
Artículo en Inglés | MEDLINE | ID: mdl-28774843

RESUMEN

We have developed a self-assembling polymeric nanocarrier to deliver the potent immunosuppressive drug Cyclosporine A (CsA) to inflammatory lesions in ulcerative colitis (UC) patients. Our nanocarrier has a high drug loading capacity and efficiently targets its CsA payload to the diseased tissue after local administration. Tissue drug levels were several orders of magnitude higher in animals suffering from a trinitrobenzene-sulfonic acid (TNBS) - induced colitis, compared to healthy control animals; no drug was detectable in the plasma, underlining the localized delivery strategy. An efficient reduction in inflammation score was obtained with a CsA dose of 1mg/mL. Therapeutic efficacy was comparable to 5-aminosalicylic acid (5-ASA), the positive control treatment in the TNBS-induced colitis model. Repetitive treatment of healthy animals with CsA nanocarriers for seven days was well tolerated with no alterations in colon histology.


Asunto(s)
Antiinflamatorios/administración & dosificación , Colitis Ulcerosa/tratamiento farmacológico , Ciclosporina/administración & dosificación , Portadores de Fármacos/administración & dosificación , Inmunosupresores/administración & dosificación , Nanopartículas/administración & dosificación , Animales , Colitis Ulcerosa/inducido químicamente , Colitis Ulcerosa/patología , Colon/efectos de los fármacos , Colon/patología , Masculino , Ratones Endogámicos C57BL , Polímeros/administración & dosificación , Ácido Trinitrobencenosulfónico
3.
J Drug Target ; 17(8): 619-26, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19589125

RESUMEN

Photodynamic therapy has emerged as a promising alternative to current cancer treatment. However, conventional photosensitizers have several limitations due to their unsuitable pharmaceutical formulations and lack of selectivity. Our strategy was to exploit the advantages of nanoparticles and the quenching-induced deactivation of the model photosensitizer hypericin to produce "activatable" drug delivery systems. Efficient fluorescence and activity quenching were achieved by increasing the drug-loading rate of nanoparticles. In vitro assays confirmed the reversibility of hypericin deactivation, as the hypericin fluorescence and photodynamic activity were recovered upon cell internalization.


Asunto(s)
Sistemas de Liberación de Medicamentos , Perileno/análogos & derivados , Fármacos Fotosensibilizantes/administración & dosificación , Fototerapia/métodos , Antracenos , Línea Celular Tumoral , Femenino , Fluorescencia , Humanos , Nanopartículas , Neoplasias Ováricas/terapia , Perileno/administración & dosificación
4.
Pharm Res ; 26(1): 118-28, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18600433

RESUMEN

PURPOSE: The feasibility of using high throughput spectroscopy for characterization and selection of physically stable protein formulations was studied. MATERIALS AND METHODS: A hundred aqueous formulations of salmon calcitonin (sCT) were prepared using 20 buffer compositions. The solutions had pH values between 2.5 and 10.5. The stability of the sCT formulations was analyzed over 1 week by the following assays: (1) protein concentration, (2) volume control by measuring pathlength, (3) turbidity (absorbance at 350 nm), (4) intrinsic tyrosine fluorescence, (5) 1-anilino-naphthalene-8-sulfonate (ANS) fluorescence, (6) Nile Red fluorescence. Addition of the dyes (Nile Red and ANS) was used to study protein conformational changes. RESULTS: After 1 day, 27 out of the 100 formulations of salmon calcitonin were stable. After 7 days, 12 stable sCT formulations remained. The best salmon calcitonin formulation was in 10 mM sodium acetate buffer with pH values between 3.5 and 5.5. CONCLUSIONS: The findings are in accordance with the sCT formulations that were patented and used commercially. This can be considered as a proof of concept for the high throughput protein formulation platform.


Asunto(s)
Conservadores de la Densidad Ósea/química , Calcitonina/química , Evaluación Preclínica de Medicamentos/métodos , Naftalenosulfonatos de Anilina/química , Conservadores de la Densidad Ósea/administración & dosificación , Tampones (Química) , Calcitonina/administración & dosificación , Química Farmacéutica , Colorantes Fluorescentes , Concentración de Iones de Hidrógeno , Oxazinas , Soluciones Farmacéuticas , Espectrometría de Fluorescencia , Espectrofotometría Ultravioleta
5.
Eur J Pharm Biopharm ; 65(2): 131-48, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17107777

RESUMEN

The formulation of protein drugs is a difficult and time-consuming process, mainly due to the complexity of protein structure and the very specific physical and chemical properties involved. Understanding protein degradation pathways is essential for the success of a biopharmaceutical drug. The present review concerns the application of high throughput screening techniques in protein formulation development. A protein high throughput formulation (HTF) platform is based on the use of microplates. Basically, the HTF platform consists of two parts: (i) sample preparation and (ii) sample analysis. Sample preparation involves automated systems for dispensing the drug and the formulation ingredients in both liquid and powder form. The sample analysis involves specific methods developed for each protein to investigate physical and chemical properties of the formulations in microplates. Examples are presented of the use of protein intrinsic fluorescence for the analysis of protein aqueous properties (e.g., conformation and aggregation). Different techniques suitable for HTF analysis are discussed and some of the issues concerning implementation are presented with reference to the use of microplates.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Preparaciones Farmacéuticas/química , Proteínas/química , Calorimetría , Química Farmacéutica , Cromatografía Liquida , Dicroismo Circular , Estabilidad de Medicamentos , Electroforesis , Polarización de Fluorescencia , Transferencia Resonante de Energía de Fluorescencia , Concentración de Iones de Hidrógeno , Luz , Espectrometría de Masas , Preparaciones Farmacéuticas/análisis , Proteínas/análisis , Dispersión de Radiación , Espectrometría de Fluorescencia , Espectrofotometría Ultravioleta , Espectroscopía Infrarroja por Transformada de Fourier , Espectrometría Raman
6.
Int J Pharm ; 286(1-2): 131-45, 2004 Nov 22.
Artículo en Inglés | MEDLINE | ID: mdl-15501010

RESUMEN

Hydrophobic porphyrins are potentially interesting molecules for the photodynamic therapy (PDT) of solid cancers or ocular vascularization diseases. Their pharmaceutical development is, however, hampered by their lipophilicity, which renders formulation difficult especially when intravenous administration is needed. Encapsulation of a lipophilic derivative of porphyrin, the meso-tetra(p-hydroxyphenyl)porphyrin (p-THPP), into polymeric biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles proved to enhance its photodynamic activity against mammary tumour cells when compared to free drug. In order to further investigate these carriers, the efficacy of the encapsulated drug was assessed on the chick embryo chorioallantoic membrane (CAM) model. First, we identified a suitable solvent for the drug in terms of p-THPP solubility and tolerability by chick embryos. This solution was used as a reference. Then, the fluorescence pharmacokinetics and the photodynamic effects of the porphyrin on CAM vessels were evaluated after intravenous administration of either a p-THPP solution (free drug) or the drug loaded into nanoparticles. The results showed that: (i) the drug remained longer in the vascular compartment when incorporated into nanoparticles and (ii) vascular effects of p-THPP after light irradiation were enhanced with nanoparticle carriers. These results are discussed taking into account the extravasation of intravascular circulating photosensitizers and its influence on PDT performance.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Nanotecnología/métodos , Tamaño de la Partícula , Porfirinas/farmacología , Animales , Embrión de Pollo/efectos de los fármacos , Pollos , Membrana Corioalantoides/efectos de los fármacos , Membrana Corioalantoides/fisiología , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Sinergismo Farmacológico , Etanol/química , Etanol/metabolismo , Etanol/farmacología , Extravasación de Materiales Terapéuticos y Diagnósticos/prevención & control , Fluorescencia , Interacciones Hidrofóbicas e Hidrofílicas , Inyecciones , Ácido Láctico/química , Ácido Láctico/metabolismo , Ácido Láctico/farmacología , Soluciones Farmacéuticas/química , Soluciones Farmacéuticas/metabolismo , Soluciones Farmacéuticas/farmacología , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/metabolismo , Fármacos Fotosensibilizantes/farmacología , Ácido Poliglicólico/química , Ácido Poliglicólico/metabolismo , Ácido Poliglicólico/farmacología , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Polímeros/metabolismo , Polímeros/farmacología , Porfirinas/química , Porfirinas/metabolismo , Solubilidad , Suiza
7.
Eur J Pharm Biopharm ; 58(1): 169-75, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15207551

RESUMEN

Two n-octenylsuccinate starch (AS) types of unknown molecular weights were assessed for ocular tolerance. Irritation potential of different solutions (containing 2 and 15% (w/w) AS) and AS stabilized emulsions (containing 15% (w/w) AS) was evaluated in vivo in rabbit eyes, using a confocal laser scanning microscope, and in vitro on treated excised pig corneas by light microscopy of histological cross sections. Both AS types were previously characterized by viscosity, osmolality and surface tension measurements. All tested solutions and emulsions showed good eye tolerance regardless of concentration and emulsifying properties suggesting AS to be a good alternative to commonly used solubilizing or emulsifying agents in ophthalmic formulations.


Asunto(s)
Córnea/efectos de los fármacos , Polímeros/administración & dosificación , Polímeros/efectos adversos , Tensoactivos/administración & dosificación , Tensoactivos/efectos adversos , Animales , Química Farmacéutica , Córnea/citología , Córnea/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Tolerancia a Medicamentos , Femenino , Masculino , Polímeros/farmacocinética , Conejos , Tensoactivos/farmacocinética , Porcinos
8.
Invest Ophthalmol Vis Sci ; 43(5): 1533-9, 2002 May.
Artículo en Inglés | MEDLINE | ID: mdl-11980871

RESUMEN

PURPOSE: Drug delivery to treat diseases of the posterior segment of the eye, such as choroidal neovascularization and its complications, is hampered by poor intraocular penetration and rapid elimination of the drug from the eye. The purpose of this study was to investigate the feasibility and tolerance of suprachoroidal injections of poly(ortho ester) (POE), a bioerodible and biocompatible polymer, as a biomaterial potentially useful for development of sustained drug delivery systems. METHODS: After tunnelization of the sclera, different formulations based on POE were injected (100 microL) into the suprachoroidal space of pigmented rabbits and compared with 1% sodium hyaluronate. Follow-up consisted of fundus observations, echography, fluorescein angiography, and histologic analysis over 3 weeks. RESULTS: After injection, POE spread in the suprachoroidal space at the posterior pole. It was well tolerated and progressively disappeared from the site of injection without sequelae. No bleeding or retinal detachment occurred. Echographic pictures showed that the material was present in the suprachoroidal space for 3 weeks. Angiography revealed minor pigment irregularities at the site of injection, but no retinal edema or necrosis. Histology showed that POE was well tolerated in the choroid. CONCLUSIONS: POE suprachoroidal injections, an easy, controllable, and reproducible procedure, were well tolerated in the rabbit eye. POE appears to be a promising biomaterial to deliver drugs focally to the choroid and the retina.


Asunto(s)
Materiales Biocompatibles/toxicidad , Coroides/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Polímeros/toxicidad , Animales , Coroides/diagnóstico por imagen , Coroides/patología , Evaluación Preclínica de Medicamentos , Espacio Extracelular/diagnóstico por imagen , Espacio Extracelular/efectos de los fármacos , Estudios de Factibilidad , Femenino , Angiografía con Fluoresceína , Ácido Hialurónico/toxicidad , Inyecciones , Conejos , Ultrasonografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA